SecurityGSK / GlaxoSmithKline plc (37733W105)
Form 6-K Count1763
Form 4 Count39
Form SC 13D/A Count28
Form SC 13G/A Count21

SEC Filings - 10K, 8K, Annual Reports

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to GlaxoSmithKline plc


DateFormTitle
2018-08-15 6-K GSK / GlaxoSmithKline plc POSITIVE HEADLINE RESULTS FOR VIIV HC ATLAS STUDY (Current Report of Foreign Issuer)
2018-08-11 6-K GSK / GlaxoSmithKline plc DIRECTOR/PDMR SHAREHOLDING (Current Report of Foreign Issuer)
2018-08-08 6-K GSK / GlaxoSmithKline plc DIRECTOR/PDMR SHAREHOLDING (Current Report of Foreign Issuer)
2018-08-07 6-K GSK / GlaxoSmithKline plc IAIN MACKAY APPOINTED GSK CHIEF FINANCIAL OFFICER (Current Report of Foreign Issuer)
2018-08-02 6-K GSK / GlaxoSmithKline plc TOTAL VOTING RIGHTS (Current Report of Foreign Issuer)
2018-07-31 6-K GSK / GlaxoSmithKline plc DIRECTOR/PDMR SHAREHOLDING (Current Report of Foreign Issuer)
2018-07-31 6-K GSK / GlaxoSmithKline plc DIRECTOR/PDMR SHAREHOLDING (Current Report of Foreign Issuer)
2018-07-27 6-K GSK / GlaxoSmithKline plc DIRECTOR/PDMR SHAREHOLDING (Current Report of Foreign Issuer)
2018-07-27 6-K GSK / GlaxoSmithKline plc CHMP RECOMMEND NUCALA FOR SEVERE ASTHMA CHILDREN (Current Report of Foreign Issuer)
2018-07-25 6-K GSK / GlaxoSmithKline plc DIRECTOR/PDMR SHAREHOLDING (Current Report of Foreign Issuer)
2018-07-25 6-K GSK / GlaxoSmithKline plc GSK AND 23ANDME AGREEMENT (Current Report of Foreign Issuer)
2018-07-25 6-K GSK / GlaxoSmithKline plc 2ND QUARTER RESULTS (Current Report of Foreign Issuer)
2018-07-24 6-K GSK / GlaxoSmithKline plc VIIV ANNOUNCES JULUCA 100 WEEK DATA AT AIDS 2018 (Current Report of Foreign Issuer)
2018-07-24 6-K GSK / GlaxoSmithKline plc VIIV SHOWS POSITIVE PHIII DATA ON TWO-DRUG COMBO (Current Report of Foreign Issuer)
2018-07-19 6-K GSK / GlaxoSmithKline plc DIRECTOR/PDMR SHAREHOLDING (Current Report of Foreign Issuer)
2018-07-17 6-K GSK / GlaxoSmithKline plc DIRECTOR/PDMR SHAREHOLDING (Current Report of Foreign Issuer)
2018-07-17 6-K GSK / GlaxoSmithKline plc DIRECTOR/PDMR SHAREHOLDING (Current Report of Foreign Issuer)
2018-07-17 6-K GSK / GlaxoSmithKline plc DIRECTOR/PDMR SHAREHOLDING (Current Report of Foreign Issuer)
2018-07-16 6-K GSK / GlaxoSmithKline plc DIRECTOR/PDMR SHAREHOLDING (Current Report of Foreign Issuer)
2018-07-16 6-K GSK / GlaxoSmithKline plc DIRECTOR/PDMR SHAREHOLDING (Current Report of Foreign Issuer)
2018-07-13 6-K GSK / GlaxoSmithKline plc DIRECTOR/PDMR SHAREHOLDING (Current Report of Foreign Issuer)
2018-07-13 6-K GSK / GlaxoSmithKline plc DIRECTOR/PDMR SHAREHOLDING (Current Report of Foreign Issuer)
2018-07-11 6-K GSK / GlaxoSmithKline plc DIRECTOR/PDMR SHAREHOLDING (Current Report of Foreign Issuer)
2018-07-02 6-K GSK / GlaxoSmithKline plc TOTAL VOTING RIGHTS (Current Report of Foreign Issuer)
2018-06-28 11-K GSK / GlaxoSmithKline plc null
2018-06-14 6-K GSK / GlaxoSmithKline plc POSITIVE HEADLINE RESULTS FOR VIIV GEMINI STUDIES (Current Report of Foreign Issuer)
2018-06-12 6-K GSK / GlaxoSmithKline plc DIRECTOR/PDMR SHAREHOLDING (Current Report of Foreign Issuer)
2018-06-12 6-K GSK / GlaxoSmithKline plc GSK ANNOUNCES CHANGES TO CORPORATE EXECUTIVE TEAM (Current Report of Foreign Issuer)
2018-06-01 6-K GSK / GlaxoSmithKline plc GSK COMPLETES CONSUMER HEALTHCARE BUYOUT (Current Report of Foreign Issuer)
2018-06-01 6-K GSK / GlaxoSmithKline plc TOTAL VOTING RIGHTS (Current Report of Foreign Issuer)
2018-05-30 SD GSK / GlaxoSmithKline plc null
2018-05-29 6-K GSK / GlaxoSmithKline plc GSK ONCE-DAILY SINGLE INHALER TRIPLE THERAPY COPD (Current Report of Foreign Issuer)
2018-05-21 6-K GSK / GlaxoSmithKline plc VIIV GRANTED EU MARKETING AUTHORISATION FOR JULUCA (Current Report of Foreign Issuer)
2018-05-15 8-A12B GSK / GlaxoSmithKline plc 8-A12B
2018-05-15 8-A12B GSK / GlaxoSmithKline plc 8-A12B
2018-05-15 8-A12B GSK / GlaxoSmithKline plc 8-A12B
2018-05-15 8-A12B GSK / GlaxoSmithKline plc 8-A12B
2018-05-15 6-K GSK / GlaxoSmithKline plc DIRECTOR/PDMR SHAREHOLDING (Current Report of Foreign Issuer)
2018-05-17 6-K GSK / GlaxoSmithKline plc 6-K (Current Report of Foreign Issuer)
2018-05-17 6-K GSK / GlaxoSmithKline plc 6-K (Current Report of Foreign Issuer)
2018-05-17 6-K GSK / GlaxoSmithKline plc 6-K (Current Report of Foreign Issuer)
2018-05-14 424B2 GSK / GlaxoSmithKline plc 424B2 (Prospectus)
2018-05-11 6-K GSK / GlaxoSmithKline plc DIRECTOR/PDMR SHAREHOLDING (Current Report of Foreign Issuer)
2018-05-11 FWP GSK / GlaxoSmithKline plc FWP
2018-05-11 FWP GSK / GlaxoSmithKline plc FWP
2018-05-11 FWP GSK / GlaxoSmithKline plc FWP
2018-05-11 FWP GSK / GlaxoSmithKline plc FWP
2018-05-11 FWP GSK / GlaxoSmithKline plc FWP
2018-05-11 FWP GSK / GlaxoSmithKline plc FWP
2018-05-10 6-K GSK / GlaxoSmithKline plc BLOCK LISTING INTERIM REVIEW (Current Report of Foreign Issuer)

Related Articles

RNVA: Rennova Health Analysis and Research Report

2018-08-18 - Asif

Business overview Rennova Health, Inc. (together with its subsidiaries, “Rennova”, “we” or the “Company”) is a provider of an expanding group of health care services for healthcare providers, patients and individuals. Beginning in 2018, the Company intends to focus on and operate two synergistic divisions: 1) Clinical diagnostics through its clinical laboratories; and 2) Hospital operations through its Big South Fork Medical Center, which opened on August 8, 2017, and a hospital in Jamestown Tennessee, including a doctor’s practice, the assets of which the company expect to acquire in the second quarter of 2018, pursuant to the terms of a definitive asset purchase agreement that the company entered into on January 31, 2018, as more fully discussed below. The company believe that its approach will produce a more sustainable business model and the capture of multiple revenue streams from medical providers, patients and hospital services. Management determined that because Big So...

BLDP: Ballard Power Systems Analysis and Research Report

2018-08-13 - Asif

Core Business At Ballard, Ballard Power Systems is building a clean energy growth company. Ballard Power Systems is recognized as a world leader in proton exchange membrane (“PEM”) fuel cell power system development and commercialization. The company's principal business is the design, development, manufacture, sale and service of PEM fuel cell products for a variety of applications, focusing on its power product markets of Heavy-Duty Motive (consisting of bus, truck, rail and marine applications), Portable Power, Material Handling and Backup Power, as well as the delivery of Technology Solutions, including engineering services, technology transfer, and the license and sale of its extensive intellectual property portfolio and fundamental knowledge for a variety of fuel cell applications. A fuel cell is an environmentally clean electrochemical device that combines hydrogen fuel with oxygen (from the air) to produce electricity. The hydrogen fuel can be obtained from natural g...

MARA: Marathon Patent Group Analysis and Research Report

2018-08-13 - Asif

Overview Marathon Patent Group was incorporated in the State of Nevada on February 23, 2010 under the name Verve Ventures, Inc. On December 7, 2011, the company changed its name to American Strategic Minerals Corporation and were engaged in exploration and potential development of uranium and vanadium minerals business. In June 2012, the company discontinued its minerals business and began to invest in real estate properties in Southern California. In October 2012, the company discontinued its real estate business when its former CEO joined the firm and the company commenced its IP licensing operations, at which time the Company’s name was changed to Marathon Patent Group, Inc. On November 1, 2017, the company entered into a merger agreement with Global Bit Ventures, Inc. (“GBV”), which is focused on mining digital assets. Marathon Patent Group has since purchased its cryptocurrency mining machines and established a data center in Canada to mine digital assets. Following the me...

Silicon Investor Message Boards

This table lists all message boards related to GSK / GlaxoSmithKline plc on message board site Silicon Investor.

After Glaxou0027s genital herpes vaccine flop, check out Agenus After Glaxou0027s genital herpes vaccine flop, check out Agenus After Glaxou0027s genital herpes vaccine flop, check out Agenus SI Pigskin Pick em SI Pigskin Pick em SI Pigskin Pick em
FOOTBALL: 1999 Pigskin Prognostication Contest FOOTBALL: 1999 Pigskin Prognostication Contest FOOTBALL: 1999 Pigskin Prognostication Contest TGSK - Great White Marine u0026 Recreation, Inc. TGSK - Great White Marine u0026 Recreation, Inc. TGSK - Great White Marine u0026 Recreation, Inc.
FOOTBALL: 1998 Pigskin Prognostication Contest FOOTBALL: 1998 Pigskin Prognostication Contest FOOTBALL: 1998 Pigskin Prognostication Contest
CUSIP: 37733W105